BioSpace News Archive

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2020.

Devonian Health Group Inc., a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that a correction had to be made to the press release issued on July 28, 2020, concerning the granting of stock options:

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) as a treatment for pediatric patients (6-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis (PsO)

Blood cancer charity Anthony Nolan has appointed Professor Antonio Pagliuca as Chief Medical and Scientific Adviser. He replaces Professor Alejandro Madrigal who left the charity in March 2020 following his retirement.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Today marks a major milestone for Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), with the initiation of our first-in-human Phase 1 clinical trial for GLR2007, our internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as a potential therapy for advanced solid tumors.

More details of the three-month program will be provided in the near future.

NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the BTIG Virtual Biotechnology Conference 2020, being held on August 10 – 11. BTIG Virtual Bio

Prothena Corporation plc announced that it will report its second quarter and first six months of 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets.

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020.